Tags

Type your tag names separated by a space and hit enter

Response to therapy of papillary thyroid cancer of known BRAF status.
Clin Endocrinol (Oxf). 2017 Dec; 87(6):815-824.CE

Abstract

OBJECTIVE

A dynamic risk stratification with modified initial estimated risk based on response to therapy and disease course is one of the crucial changes adopted recently by the American Thyroid Association (ATA). This approach focuses on an individualized risk-adapted approach to the management of differentiated thyroid cancer. The BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). However, the prognostic value of this mutation remains unclear. The aim of this study was to examine the relation between the BRAF V600E status in PTC and all ATA response-to-therapy categories, as well as the recurrence and persistence of both biochemical disease and structural disease.

PATIENTS

Unselected PTC cases with known BRAF status diagnosed from 2000 to 2013 and actively monitored at one institution (n=723) were reviewed retrospectively. The association between the BRAF V600E mutation and clinicopathological characteristics, ATA 2015 response-to-therapy category, recurrence after a period of no evidence of disease (NED) and persistent biochemical or structural disease, was analysed.

RESULTS

BRAF V600E was found in 65.7% (475/723) of PTC cases. Although BRAF mutation status correlated significantly with certain clinicopathological prognostic factors, there was no correlation with any of the response-to-therapy categories. Recurrences and persistent biochemical or structural disease were not associated with BRAF status.

CONCLUSIONS

Our data are consistent with those of other studies reporting a positive relation between BRAF V600E mutation and poor prognostic factors in PTC; however, the BRAF status did not significantly correlate with a response to therapy.

Authors+Show Affiliations

Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland. The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Molecular Diagnostics, Holycross Cancer Centre, Kielce, Poland. Department of Surgery and Surgical Nursing with the Scientific Research Laboratory, The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Surgical Pathology, Holycross Cancer Centre, Kielce, Poland.Department of Surgical Pathology, Medical University of Silesia, Katowice, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland.Department of Probability Theory and Statistics Institute of Mathematics, Faculty of Mathematics and Natural Science, Jan Kochanowski University, Kielce, Poland.Departments of Molecular Diagnostics, Holycross Cancer Centre, Kielce, Poland.The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland. Departments of Clinical Oncology, Holycross Cancer Centre, Kielce, Poland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28718951

Citation

Kowalska, Aldona, et al. "Response to Therapy of Papillary Thyroid Cancer of Known BRAF Status." Clinical Endocrinology, vol. 87, no. 6, 2017, pp. 815-824.
Kowalska A, Walczyk A, Kowalik A, et al. Response to therapy of papillary thyroid cancer of known BRAF status. Clin Endocrinol (Oxf). 2017;87(6):815-824.
Kowalska, A., Walczyk, A., Kowalik, A., Pałyga, I., Gąsior-Perczak, D., Trybek, T., Kopczyński, J., Kajor, M., Mikina, E., Szymonek, M., Gadawska-Juszczyk, K., Szyska-Skrobot, D., Lizis-Kolus, K., Hurej, S., Chrapek, M., Chłopek, M., & Góźdź, S. (2017). Response to therapy of papillary thyroid cancer of known BRAF status. Clinical Endocrinology, 87(6), 815-824. https://doi.org/10.1111/cen.13423
Kowalska A, et al. Response to Therapy of Papillary Thyroid Cancer of Known BRAF Status. Clin Endocrinol (Oxf). 2017;87(6):815-824. PubMed PMID: 28718951.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Response to therapy of papillary thyroid cancer of known BRAF status. AU - Kowalska,Aldona, AU - Walczyk,Agnieszka, AU - Kowalik,Artur, AU - Pałyga,Iwona, AU - Gąsior-Perczak,Danuta, AU - Trybek,Tomasz, AU - Kopczyński,Janusz, AU - Kajor,Maciej, AU - Mikina,Estera, AU - Szymonek,Monika, AU - Gadawska-Juszczyk,Klaudia, AU - Szyska-Skrobot,Dorota, AU - Lizis-Kolus,Katarzyna, AU - Hurej,Stefan, AU - Chrapek,Magdalena, AU - Chłopek,Małgorzata, AU - Góźdź,Stanisław, Y1 - 2017/08/04/ PY - 2017/02/19/received PY - 2017/05/28/revised PY - 2017/07/14/accepted PY - 2017/7/19/pubmed PY - 2018/7/3/medline PY - 2017/7/19/entrez KW - BRAF mutation KW - papillary thyroid cancer KW - response to therapy KW - risk stratification SP - 815 EP - 824 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 87 IS - 6 N2 - OBJECTIVE: A dynamic risk stratification with modified initial estimated risk based on response to therapy and disease course is one of the crucial changes adopted recently by the American Thyroid Association (ATA). This approach focuses on an individualized risk-adapted approach to the management of differentiated thyroid cancer. The BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). However, the prognostic value of this mutation remains unclear. The aim of this study was to examine the relation between the BRAF V600E status in PTC and all ATA response-to-therapy categories, as well as the recurrence and persistence of both biochemical disease and structural disease. PATIENTS: Unselected PTC cases with known BRAF status diagnosed from 2000 to 2013 and actively monitored at one institution (n=723) were reviewed retrospectively. The association between the BRAF V600E mutation and clinicopathological characteristics, ATA 2015 response-to-therapy category, recurrence after a period of no evidence of disease (NED) and persistent biochemical or structural disease, was analysed. RESULTS: BRAF V600E was found in 65.7% (475/723) of PTC cases. Although BRAF mutation status correlated significantly with certain clinicopathological prognostic factors, there was no correlation with any of the response-to-therapy categories. Recurrences and persistent biochemical or structural disease were not associated with BRAF status. CONCLUSIONS: Our data are consistent with those of other studies reporting a positive relation between BRAF V600E mutation and poor prognostic factors in PTC; however, the BRAF status did not significantly correlate with a response to therapy. SN - 1365-2265 UR - https://www.unboundmedicine.com/medline/citation/28718951/Response_to_therapy_of_papillary_thyroid_cancer_of_known_BRAF_status_ L2 - https://doi.org/10.1111/cen.13423 DB - PRIME DP - Unbound Medicine ER -